These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30446802)

  • 1. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
    García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
    Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
    Latagliata R; Attolico I; Trawinska MM; Capodanno I; Annunziata M; Elena C; Luciano L; Crugnola M; Bergamaschi M; Bonifacio M; Baratè C; Mauro E; Binotto G; Sgherza N; Aguzzi C; Monteleone B; Sorà F; Caocci G; Luzi D; Mariggiò E; Scaffidi L; Cattaneo D; Gozzini A; Di Veroli A; Abruzzese E; Galimberti S; Iurlo A; Specchia G; Breccia M
    Hematol Oncol; 2021 Aug; 39(3):401-408. PubMed ID: 33617659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
    Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
    J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
    Takahashi N; Nakaseko C; Kobayashi Y; Miyamura K; Ono C; Koide Y; Fujii Y; Ohnishi K
    Int J Hematol; 2017 Sep; 106(3):398-410. PubMed ID: 28409328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
    Kota V; Brümmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim DW; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
    Leuk Res; 2021 Dec; 111():106690. PubMed ID: 34673442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
    Cortes JE; Kantarjian HM; Brümmendorf TH; Kim DW; Turkina AG; Shen ZX; Pasquini R; Khoury HJ; Arkin S; Volkert A; Besson N; Abbas R; Wang J; Leip E; Gambacorti-Passerini C
    Blood; 2011 Oct; 118(17):4567-76. PubMed ID: 21865346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
    Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
    Cortes JE; Kantarjian HM; Mauro MJ; An F; Nick S; Leip E; Gambacorti-Passerini C; Brümmendorf TH
    Eur J Haematol; 2021 Jun; 106(6):808-820. PubMed ID: 33638218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
    Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
    Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
    Tiribelli M; Abruzzese E; Capodanno I; Sorà F; Trabacchi E; Iurlo A; Luciano L; Binotto G; Bonifacio M; Annunziata M; Crugnola M; Fanin R
    Ann Hematol; 2019 Nov; 98(11):2609-2611. PubMed ID: 31529281
    [No Abstract]   [Full Text] [Related]  

  • 14. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
    Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
    Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
    García-Gutiérrez V; Martinez-Trillos A; Lopez Lorenzo JL; Bautista G; Martin Mateos ML; Alvarez-Larrán A; Iglesias Pérez A; Romo Collado A; Fernandez A; Portero A; Cuevas B; Ruiz C; Romero E; Ortega F; Mata I; Tallón J; García Garay Mdel C; Ramirez Sánchez MJ; de Las Heras N; Giraldo P; Bobillo S; Guinea JM; Deben G; Valencia S; Sebrango A; Boqué C; Maestro B; Steegmann JL
    Am J Hematol; 2015 May; 90(5):429-33. PubMed ID: 25683327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Unkrig C; Enzmann H; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2014 Apr; 19(4):421-5. PubMed ID: 24668331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
    Cortes JE; Khoury HJ; Kantarjian HM; Lipton JH; Kim DW; Schafhausen P; Matczak E; Leip E; Noonan K; Brümmendorf TH; Gambacorti-Passerini C
    Am J Hematol; 2016 Dec; 91(12):1206-1214. PubMed ID: 27531525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Smith BD; Brümmendorf TH; Roboz GJ; Gambacorti-Passerini C; Charbonnier A; Viqueira A; Leip E; Purcell S; Goldman EH; Giles F; Ernst T; Hochhaus A; Rosti G
    Leuk Res; 2024 Apr; 139():107481. PubMed ID: 38484432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.